Clinical trials: Cancer of Skin
- Condition Cancer of Skin
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Melanoma, Head and Neck Cancer
Evaluation of Intraoperative Usage of Sentinella in Detecting Sentinel Lymph Nodes
The aim of this study is to investigate whether the Sentinella camera improves intraoperative detection and removal of sentinel lymph nodes (SLNs) when used in conjunction with standard detection methods.
- Conditions
- Melanoma, Head and Neck Cancer, Breast Cancer
- Trial name
- NCT02416336
- Testing
- Sentinella Intraoperative imaging protocol
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Oncovision Inc
Malignant Melanoma, Carcinoma, Non-Small-Cell Lung
A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement
First-in-human study to assess safety, tolerability, PK, and preliminary activity of PF-07284890 as a single agent and in combination with binimetinib in participants with BRAF V600-mutated advanced solid tumor malignancies with…
- Conditions
- Malignant Melanoma, Carcinoma, Non-Small-Cell Lung, Brain Neoplasms, Primary, Brain Neoplasms
- Trial name
- NCT04543188
- Testing
- PF-07284890, Binimetinib, Midazolam
- Where
- 45 sites in United States, Canada and 1 more
- Volunteers
- 65 people
- Sponsor
- Pfizer
Juvenile Idiopathic Arthritis
A Study of Juvenile Idiopathic Arthritis Patients Given Abatacept and the Number of Infections or Malignancies That Occur
This study will determine the incidences of infections and malignancies among JIA patients treated with abatacept
- Trial name
- NCT03769558
- Testing
- Non-Interventional
- Where
- United States
- Volunteers
- 264 people
- Sponsor
- Bristol-Myers Squibb
Breast Cancer, Radiation Dermatitis
A DB Randomized Study of R1 and R2 WaterJel / AloeVera Jell in Prevention of Radiation Dermatitis in Breast Cancer
The purpose of this study is to evaluate the effects of topical R1 and R2 for prophylaxis of acute radiation dermatitis in patients with breast cancer receiving radiotherapy.
- Conditions
- Breast Cancer, Radiation Dermatitis, Erythema
- Trial name
- NCT01597921
- Where
- Israel
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Water-Jel
Leptomeningeal Metastasis, Leptomeningeal Disease
A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide
The FORESEE Study is a multi-center, prospective clinical trial enrolling patients with Breast or Non-Small Cell Lung Cancer (NSCLC) who have suspicious or confirmed Leptomeningeal Metastases (LM).
- Conditions
- Leptomeningeal Metastasis, Leptomeningeal Disease, Leptomeningeal Neoplasms, Breast Cancer
- Trial name
- FORESEE (NCT05414123)
- Testing
- CNSide
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Biocept, Inc.
Breast Cancer
A Prospective Observational Study of Clinical Outcomes for the NanoString® Technologies Prosigna Gene Signature Assay
The primary objective of this study is to assess the extent to which the Prosigna™ Breast Cancer Prognostic Gene Signature Assay affects the medical oncologist's treatment recommendations regarding adjuvant chemotherapy and…
- Trial name
- NCT01899079
- Where
- 7 sites in Spain
- Volunteers
- 217 people
- Sponsor
- NanoString Technologies, Inc.
Melanoma
Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma
The purpose of this study is to assess the safety profile of vemurafenib, 960 mg, administered for 6 weeks, followed by ipilimumab monotherapy in patients with BRAF V600 mutated advanced/metastatic melanoma.
- Trial name
- NCT01673854
- Testing
- Ipilimumab, Vemurafenib
- Where
- 14 sites in United States
- Volunteers
- 70 people
- Sponsor
- Bristol-Myers Squibb
Breast Neoplasms
Screening Tool Artificial Intelligence-based for Predicting the Genetic Risk of BREAST Cancer
It is a retrospective observational study that will include female patients aged 18 years or older, who were treated between 2017 and 2024, in both public and private institutions, and identified as at high genetic risk by breast…
- Trial name
- STAR-BREAST (NCT07070128)
- Where
- 3 sites in Brazil
- Volunteers
- 800 people
- Sponsor
- AstraZeneca
Skin Cancer, Gastrointestinal Cancer
Electroporation for Cancer Treatment Real World Registry
This registry aims to assess real-world long-term disease outcomes for patients treated using reversible electroporation and a chemotherapeutic or calcium; in particular tumour response rates and recurrence rates.
- Trial name
- PIONEER (NCT04929912)
- Where
- United Kingdom
- Volunteers
- 1,000 people
- Sponsor
- Mirai Medical
Cancer, Metastatic, Cancer
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and…
- Conditions
- Cancer, Metastatic, Cancer, Cancer of Pancreas, Cancer of Liver
- Trial name
- NCT03452774
- Testing
- Clinical Trial Matching
- Where
- 68 sites in United States, Puerto Rico
- Volunteers
- 50,000 people
- Sponsor
- Massive Bio, Inc.
Actinic Keratosis
A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled Therapeutic Equivalence Study of Three Imiquimod Cream 5% Treatments for Patients With Actinic Keratosis
Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Bio-equivalence Study
- Trial name
- NCT00859105
- Testing
- Imiquimod 5%: manufactured by Apotex, Adara 5% Cream US, Adara 5% Cream Canada
- Volunteers
- 497 people
- Sponsor
- Apotex Inc.
Breast Cancer
A Study of Clinical Outcomes for the NanoString® Technologies Prosigna™ Gene Signature Assay
The primary objective of this study is to evaluate the impact of the result of the Prosigna Test (assay) on the therapeutic decision of adjuvant therapy (chemotherapy and hormone therapy) in patients suffering from early-stage…
- Trial name
- NCT02395575
- Where
- France
- Volunteers
- 200 people
- Sponsor
- NanoString Technologies, Inc.
Melanoma
Program for Pembrolizumab (MK-3475) in Participants With Metastatic Melanoma Who Have Failed Standard of Care Therapy Including Ipilimumab (MK-3475-030)
This is an expanded access program (EAP) for participants who have progressed after prior systemic therapy including ipilimumab, and V-raf murine sarcoma viral oncogene homolog B1 (BRAF) inhibitor or mitogen-activated protein…
- Trial name
- NCT02083484
- Testing
- Pembrolizumab
- Sponsor
- Merck Sharp & Dohme LLC
Melanoma
A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma
The purpose of this study is to demonstrate that the study drug exposure level of the nivolumab + relatlimab FDC subcutaneous (SC) formulation is not worse than nivolumab + relatlimab FDC intravenous (IV) administration in…
- Trial name
- RELATIVITY-127 (NCT05625399)
- Testing
- Nivolumab + Relatlimab, rHuPH20
- Where
- 149 sites in United States, Australia and 17 more
- Volunteers
- 579 people
- Sponsor
- Bristol-Myers Squibb
Chronic Pain
Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Opioid Tolerant Pediatric Subjects
The purpose of this study is to evaluate the effectiveness, tolerability, and safety of oxymorphone immediate release (IR) oral liquid as an analgesic in pediatric subjects having severe to moderate chronic pain.
- Trial name
- NCT01206907
- Testing
- oxymorphone IR
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Breast Cancer
Fulvestrant (FASLODEX™) as a Treatment in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer
The purpose of this study is to evaluate fulvestrant in the preliminary stage of breast cancer treatment and assess the relationship between dose, exposure, degree of reduction in tumor markers, and efficacy in postmenopausal…
- Trial name
- NCT00093002
- Testing
- Fulvestrant
- Where
- 31 sites in United States, Austria and 4 more
- Volunteers
- 179 people
- Sponsor
- AstraZeneca
Non-Small Cell Lung Cancer, Medullary Thyroid Cancer
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of selpercatinib (also known as LOXO-292) administered orally to participants…
- Conditions
- Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor
- Trial name
- LIBRETTO-001 (NCT03157128)
- Testing
- LOXO-292
- Where
- 85 sites in United States, Australia and 14 more
- Volunteers
- 857 people
- Sponsor
- Eli Lilly and Company
Breast Cancer
Clinical Trial of Quantitative Detection Kit for Hsp90α in Breast Cancer
Detect plasma Hsp90α concentration of breast cancer patients, healthy volunteers, benign breast diseases patients
- Trial name
- NCT02324101
- Testing
- Hsp90
- Where
- China
- Volunteers
- 1,100 people, healthy volunteers welcome
- Sponsor
- Beijing Protgen Biotechnology Development Co., Ltd.
Vitiligo, Pediatric ALL
Efficacy and Safety of 308-nm Excimer Lamp Combined With Tacrolimus vs Tacrolimus as Monotherapy in Treating Vitiligo on Children
Vitiligo is a auto immune that impact 2% of the global population, regardless from the phototype. Even though it affects patients in a physical way through loss of pigmentation, it is also impacting them on a mental/emotional…
- Conditions
- Vitiligo, Pediatric ALL, Dermatologic Disease, Autoimmune Diseases
- Trial name
- NCT06035614
- Testing
- exciplex, Tacrolimus ointment
- Where
- Jordan
- Volunteers
- 50 people
- Sponsor
- Clarteis
Melanoma
Study of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma
The purpose of this clinical research study is to compare the best overall response rate (BORR)(as per modified WHO criteria) in patients with previously treated, therapy-refractory, or -intolerant, Stage III (unresectable) or…
- Trial name
- NCT00289640
- Testing
- ipilimumab (MDX-010, BMS-734016), Ipilimumab
- Where
- 62 sites in United States, Australia and 8 more
- Volunteers
- 210 people
- Sponsor
- Bristol-Myers Squibb